On Friday, Following Stocks were among the “Top 100 Gainers” In U.S. Stock Exchange: NQ Mobile Inc (ADR) (NYSE:NQ), ISIS Pharmaceuticals, Inc (NASDAQ:ISIS), Lattice Semiconductor (NASDAQ:LSCC), Sucampo Pharmaceuticals, Inc (NASDAQ:SCMP)
NQ Mobile Inc (ADR) (NYSE:NQ), shares picked up 3.64%, and closed at $3.99. The stock has price to sale ratio of 1.62, however, price to book ratio is 0.66. With recent incline, the year-to-date (YTD) performance reflected a 2.05% gain above last year. During the past month the stocks lose -0.25%, bringing three-month performance to -7.64% and six-month performance to -34.80%. The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).
NQ Mobile Inc. provides mobile Internet services in the People’s Republic of China and internationally. The company provides products and services in the areas of mobile security, privacy, productivity, personalized cloud, and family protection. It operates through two segments, Consumer and Enterprise. The company offers NQ Mobile Security, a mobile security product that protects users’ mobile voice and data from malicious software, hacking, phishing, and privacy intrusion; and mobile malware scanning, Internet firewall, financial and social media account and communication protection, phone performance optimization, and call and SMS blocking services.
ISIS Pharmaceuticals, Inc (NASDAQ:ISIS), raised 3.63%, and closed at $63.37. The company holds the market capitalization of $7.54B. For the last twelve months, the stock was able to keep return on equity at -11.60%, while return on assets at -4.60%, in response to its return on investment at -5.70%. Its 20-day moving average declined -9.05%, below 50-day moving average of -6.64%, above 200-day moving average of 28.53% from the latest market price of $63.37. The mean recommendation of analysts for this stock is 2.70.(where 1=Buy, 5=Sale).
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 38 drugs in development for the treatment of various diseases, counting cardiovascular and metabolic diseases; severe and rare diseases, which comprise neurological disorders; and cancer.
Lattice Semiconductor (NASDAQ:LSCC), enhanced 3.62%, and closed at $6.59. The stock volatility for the week is 3.21%, while for the month remained 2.38%. The company holds consensus target price of $8.88.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 0.40 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 110.50% and Annual EPS growth for the past 5 years is considered as 54.00%.
The mean recommendation of analysts for this stock is 1.30. (where 1=Buy, 5=Sale).
Lattice Semiconductor Corporation designs, develops, and markets programmable logic products and related software in Asia, Europe, and the Americas. It offers products based on field programmable gate arrays (FPGAs) and complex programmable logic devices (CPLDs) architectures. The company provides various lattice products, such as LatticeECP families, which are designed for customers who need programmable logic devices that offer digital signal processing capabilities; and MachXO families of versatile non-volatile reconfigurable FPGAs, which are designed for applications that are implemented using CPLDs or low-density FPGAs. It also provides iCE40 families that are designed to meet the shrinking power budgets and space constrained environments of handheld products.
Sucampo Pharmaceuticals, Inc (NASDAQ:SCMP), rose 3.57%, and closed at $14.50. The company has the market capitalization of $651.06M. The beta value of the stock is 1.58. On the other hand the stock’s volatility for the week is 6.46%, and for the month is 7.31%. The stock’s price to book ratio is 7.75, however price to sale ratio is 5.64. Analyst’s mean recommendation regarding this stock is 2.50. (where 1=Buy, 5=Sale).
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs in the Americas, Europe, and Asia. It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders, in addition to other therapeutic applications of drug technologies. The company’s product pipeline comprises AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
